CompletedPhase 2NCT02019667

Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency

Studying Disorder of gamma-aminobutyric acid metabolism

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Sara K Inati, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Intervention: SGS-742(drug)
Enrollment: 19 enrolled
Eligibility: 4 years · All sexes
Timeline: 2014 – 2019

Study locations (2)

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Washington State University, Pullman, Washington, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02019667 on ClinicalTrials.gov

← Back to all trials